Nuestro grupo organiza más de 3000 Series de conferencias Eventos cada año en EE. UU., Europa y América. Asia con el apoyo de 1.000 sociedades científicas más y publica más de 700 Acceso abierto Revistas que contienen más de 50.000 personalidades eminentes, científicos de renombre como miembros del consejo editorial.

Revistas de acceso abierto que ganan más lectores y citas
700 revistas y 15 000 000 de lectores Cada revista obtiene más de 25 000 lectores

Abstracto

Analysis of Mutagenic Potential of Therapeutic Vaccine Based on BPV-1 E6 Recombinant Protein Combined with Different Adjuvants

Rodrigo Pinheiro Araldi1,2, Diego Grando Módolo1, Jacqueline Mazzuchelli de Souza1,2, Rodrigo Franco de Carvalho1, Lucinéia dos Santos3, Isabel Cristina Cherici Camargo3, Edislane Barreiros de Souza3 and Rita de Cassia Stocco1*

Bovine papillomavirus is a worldwide distributed virus that affects at least 60% of Brazilian cattle herd, causing significant economic loses. Considering the great number of BPV-infected bovines, therapeutic vaccines, such those based on E6 protein, are mandatory to control the BPV-related diseases. However, the choice of the adjuvant remains challenging the vaccinology field, since adjuvants are associated with local and systemic reactions. Thus, this study analyzed the cytotoxic and mutagenic potential of BPV-1 E6 protein-based vaccine formulations using different adjuvants: aluminum hydroxide, complete and incomplete Freund’s adjuvants and two anti-oxidant saponin-rich extracts obtained from Agave sisalana-alcoholic and acid hydrolysis extract. Results of these analyzes suggest that acid hydrolysis extract from A. sisalana is an alternative and useful candidate for therapeutic vaccines, being able to reduce the mutagenic potential of antigen.

Descargo de responsabilidad: este resumen se tradujo utilizando herramientas de inteligencia artificial y aún no ha sido revisado ni verificado.